Alyeska Investment Group’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$30.4M Sell
518,043
-290,527
-36% -$12.2M 0.08% 279
2026
Q1
$26M Buy
808,570
+207,014
+34% +$7.66M 0.07% 285
2025
Q4
$25.3M Buy
601,556
+293,503
+95% +$11.8M 0.07% 277
2025
Q3
$10.6M Buy
+308,053
New +$8.84M 0.03% 368
2021
Q4
Sell
-203,129
Closed -$9.44M 733
2021
Q3
$9.44M Buy
203,129
+2,559
+1% +$112K 0.12% 207
2021
Q2
$8.02M Buy
200,570
+17,645
+10% +$755K 0.09% 250
2021
Q1
$9.83M Buy
+182,925
New +$10.5M 0.13% 205
2019
Q4
Sell
-204,879
Closed -$4.92M 498
2019
Q3
$4.92M Sell
204,879
-6,303
-3% -$168K 0.07% 229
2019
Q2
$6.02M Buy
+211,182
New +$5.28M 0.08% 213
2014
Q2
Sell
-185,919
Closed -$3.19M 459
2014
Q1
$3.19M Sell
185,919
-55,838
-23% -$892K 0.09% 233
2013
Q4
$3.5M Buy
+241,757
New +$3.15M 0.14% 193

Other funds holding VCYT

Alyeska Investment Group's VCYT Position: Q2 2026 in Review

Alyeska Investment Group reduced its Veracyte (VCYT) stake by 36% in Q2 2026, selling an estimated $12.2M and leaving 518,043 shares worth $30.4M. The position accounts for 0.08% of the portfolio, ranked #279.

Alyeska Investment Group first reported a position in VCYT in Q4 2013 and has held it in 11 quarters since. 371 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Alyeska Investment Group held 518,043 shares of Veracyte worth $30.4M as of Q2 2026.
  • Alyeska Investment Group sold 290,527 Veracyte shares in Q2 2026, an estimated $12.2M.
  • Veracyte made up 0.08% of Alyeska Investment Group's portfolio in Q2 2026, its #279 holding.
  • Alyeska Investment Group first reported a position in Veracyte in Q4 2013 and has held it in 11 quarters since.
  • 371 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.